Cargando…

Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study

BACKGROUND: Despite aggressive treatment regimens comprising surgery and radiochemotherapy, glioblastoma (GBM) remains a cancer entity with very poor prognosis. The development of novel, combined modality approaches necessitates adequate preclinical model systems and therapy regimens that closely re...

Descripción completa

Detalles Bibliográficos
Autores principales: Stegen, Benjamin, Nieto, Alexander, Albrecht, Valerie, Maas, Jessica, Orth, Michael, Neumaier, Klement, Reinhardt, Sabine, Weick-Kleemann, Moritz, Goetz, Wilfried, Reinhart, Merle, Parodi, Katia, Belka, Claus, Niyazi, Maximilian, Lauber, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977274/
https://www.ncbi.nlm.nih.gov/pubmed/31969174
http://dx.doi.org/10.1186/s13014-020-1470-2
_version_ 1783490472734359552
author Stegen, Benjamin
Nieto, Alexander
Albrecht, Valerie
Maas, Jessica
Orth, Michael
Neumaier, Klement
Reinhardt, Sabine
Weick-Kleemann, Moritz
Goetz, Wilfried
Reinhart, Merle
Parodi, Katia
Belka, Claus
Niyazi, Maximilian
Lauber, Kirsten
author_facet Stegen, Benjamin
Nieto, Alexander
Albrecht, Valerie
Maas, Jessica
Orth, Michael
Neumaier, Klement
Reinhardt, Sabine
Weick-Kleemann, Moritz
Goetz, Wilfried
Reinhart, Merle
Parodi, Katia
Belka, Claus
Niyazi, Maximilian
Lauber, Kirsten
author_sort Stegen, Benjamin
collection PubMed
description BACKGROUND: Despite aggressive treatment regimens comprising surgery and radiochemotherapy, glioblastoma (GBM) remains a cancer entity with very poor prognosis. The development of novel, combined modality approaches necessitates adequate preclinical model systems and therapy regimens that closely reflect the clinical situation. So far, image-guided, fractionated radiotherapy of orthotopic GBM models represents a major limitation in this regard. METHODS: GL261 mouse GBM cells were inoculated into the right hemispheres of C57BL/6 mice. Tumor growth was monitored by contrast-enhanced conebeam CT (CBCT) scans. When reaching an average volume of approximately 7 mm(3), GBM tumors were irradiated with daily fractions of 2 Gy up to a cumulative dose of 20 Gy in different beam collimation settings. For treatment planning and tumor volume follow-up, contrast-enhanced CBCT scans were performed twice per week. Daily repositioning of animals was achieved by alignment of bony structures in native CBCT scans. When showing neurological symptoms, mice were sacrificed by cardiac perfusion. Brains, livers, and kidneys were processed into histologic sections. Potential toxic effects of contrast agent administration were assessed by measurement of liver enzyme and creatinine serum levels and by histologic examination. RESULTS: Tumors were successfully visualized by contrast-enhanced CBCT scans with a detection limit of approximately 2 mm(3), and treatment planning could be performed. For daily repositioning of the animals, alignment of bony structures in native CT scans was well feasible. Fractionated irradiation caused a significant delay in tumor growth translating into significantly prolonged survival in clear dependence of the beam collimation setting and margin size. Brain sections revealed tumors of similar appearance and volume on the day of euthanasia. Importantly, the repeated contrast agent injections were well tolerated, as liver enzyme and creatinine serum levels were only subclinically elevated, and liver and kidney sections displayed normal histomorphology. CONCLUSIONS: Contrast-enhanced, CT-based, fractionated radiation of orthotopic mouse GBM represents a versatile preclinical technique for the development and evaluation of multimodal radiotherapeutic approaches in combination with novel therapeutic agents in order to accelerate translation into clinical testing.
format Online
Article
Text
id pubmed-6977274
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69772742020-01-28 Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study Stegen, Benjamin Nieto, Alexander Albrecht, Valerie Maas, Jessica Orth, Michael Neumaier, Klement Reinhardt, Sabine Weick-Kleemann, Moritz Goetz, Wilfried Reinhart, Merle Parodi, Katia Belka, Claus Niyazi, Maximilian Lauber, Kirsten Radiat Oncol Research BACKGROUND: Despite aggressive treatment regimens comprising surgery and radiochemotherapy, glioblastoma (GBM) remains a cancer entity with very poor prognosis. The development of novel, combined modality approaches necessitates adequate preclinical model systems and therapy regimens that closely reflect the clinical situation. So far, image-guided, fractionated radiotherapy of orthotopic GBM models represents a major limitation in this regard. METHODS: GL261 mouse GBM cells were inoculated into the right hemispheres of C57BL/6 mice. Tumor growth was monitored by contrast-enhanced conebeam CT (CBCT) scans. When reaching an average volume of approximately 7 mm(3), GBM tumors were irradiated with daily fractions of 2 Gy up to a cumulative dose of 20 Gy in different beam collimation settings. For treatment planning and tumor volume follow-up, contrast-enhanced CBCT scans were performed twice per week. Daily repositioning of animals was achieved by alignment of bony structures in native CBCT scans. When showing neurological symptoms, mice were sacrificed by cardiac perfusion. Brains, livers, and kidneys were processed into histologic sections. Potential toxic effects of contrast agent administration were assessed by measurement of liver enzyme and creatinine serum levels and by histologic examination. RESULTS: Tumors were successfully visualized by contrast-enhanced CBCT scans with a detection limit of approximately 2 mm(3), and treatment planning could be performed. For daily repositioning of the animals, alignment of bony structures in native CT scans was well feasible. Fractionated irradiation caused a significant delay in tumor growth translating into significantly prolonged survival in clear dependence of the beam collimation setting and margin size. Brain sections revealed tumors of similar appearance and volume on the day of euthanasia. Importantly, the repeated contrast agent injections were well tolerated, as liver enzyme and creatinine serum levels were only subclinically elevated, and liver and kidney sections displayed normal histomorphology. CONCLUSIONS: Contrast-enhanced, CT-based, fractionated radiation of orthotopic mouse GBM represents a versatile preclinical technique for the development and evaluation of multimodal radiotherapeutic approaches in combination with novel therapeutic agents in order to accelerate translation into clinical testing. BioMed Central 2020-01-22 /pmc/articles/PMC6977274/ /pubmed/31969174 http://dx.doi.org/10.1186/s13014-020-1470-2 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Stegen, Benjamin
Nieto, Alexander
Albrecht, Valerie
Maas, Jessica
Orth, Michael
Neumaier, Klement
Reinhardt, Sabine
Weick-Kleemann, Moritz
Goetz, Wilfried
Reinhart, Merle
Parodi, Katia
Belka, Claus
Niyazi, Maximilian
Lauber, Kirsten
Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
title Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
title_full Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
title_fullStr Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
title_full_unstemmed Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
title_short Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
title_sort contrast-enhanced, conebeam ct-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977274/
https://www.ncbi.nlm.nih.gov/pubmed/31969174
http://dx.doi.org/10.1186/s13014-020-1470-2
work_keys_str_mv AT stegenbenjamin contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT nietoalexander contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT albrechtvalerie contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT maasjessica contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT orthmichael contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT neumaierklement contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT reinhardtsabine contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT weickkleemannmoritz contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT goetzwilfried contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT reinhartmerle contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT parodikatia contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT belkaclaus contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT niyazimaximilian contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy
AT lauberkirsten contrastenhancedconebeamctbasedfractionatedradiotherapyandfollowupmonitoringoforthotopicmouseglioblastomaaproofofconceptstudy